Form 8-K - Current report:
SEC Accession No. 0001193125-24-265627
Filing Date
2024-11-26
Accepted
2024-11-26 07:17:53
Documents
13
Period of Report
2024-11-24
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d856104d8k.htm   iXBRL 8-K 34919
  Complete submission text file 0001193125-24-265627.txt   159854

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA srpt-20241124.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20241124_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20241124_pre.xml EX-101.PRE 11262
15 EXTRACTED XBRL INSTANCE DOCUMENT d856104d8k_htm.xml XML 3640
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 241498152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)